| Q53245219 | A 4-MicroRNA signature can discriminate primary lymphomas from anaplastic carcinomas in thyroid cytology smears. |
| Q42230002 | A miRNA expression signature that separates between normal and malignant prostate tissues. |
| Q36437698 | A systematic analysis of miRNA transcriptome in Marek's disease virus-induced lymphoma reveals novel and differentially expressed miRNAs. |
| Q53323040 | Activation of the polycomb repressive complex pathway in the bone marrow resident cells of diffuse large B-cell lymphoma patients. |
| Q41153398 | Acute resistance exercise modulates microRNA expression profiles: Combined tissue and circulatory targeted analyses. |
| Q46515733 | Altered miRNA and gene expression in acute myeloid leukemia with complex karyotype identify networks of prognostic relevance |
| Q38773915 | An oncogenic Ezh2 mutation induces tumors through global redistribution of histone 3 lysine 27 trimethylation. |
| Q47571295 | Anti-leukemic activity of microRNA-26a in a chronic lymphocytic leukemia mouse model. |
| Q35870390 | BMI-1, a promising therapeutic target for human cancer |
| Q39675624 | CPEB2, CPEB3 and CPEB4 are coordinately regulated by miRNAs recognizing conserved binding sites in paralog positions of their 3'-UTRs |
| Q53265216 | CagA mediates epigenetic regulation to attenuate let-7 expression in Helicobacter pylori-related carcinogenesis. |
| Q33667093 | Cancer angiogenesis induced by Kaposi sarcoma-associated herpesvirus is mediated by EZH2. |
| Q36386431 | Cancer mediates effector T cell dysfunction by targeting microRNAs and EZH2 via glycolysis restriction. |
| Q33988586 | Carboxyl-terminal truncated HBx regulates a distinct microRNA transcription program in hepatocellular carcinoma development |
| Q34391443 | Cardio-miRNAs and onco-miRNAs: circulating miRNA-based diagnostics for non-cancerous and cancerous diseases |
| Q35651246 | Cellular microRNA miR-26a suppresses replication of porcine reproductive and respiratory syndrome virus by activating innate antiviral immunity |
| Q39243402 | Characterization of the EZH2-MMSET histone methyltransferase regulatory axis in cancer |
| Q54285415 | Comparative microarray analysis of microRNA expression profiles in primary cutaneous malignant melanoma, cutaneous malignant melanoma metastases, and benign melanocytic nevi. |
| Q64253022 | Comparison of the Transcriptomes and Proteomes of Serum Exosomes from Marek's Disease Virus-Vaccinated and Protected and Lymphoma-Bearing Chickens |
| Q38226703 | Consideration of GREB1 as a potential therapeutic target for hormone-responsive or endocrine-resistant cancers |
| Q94350214 | Context-dependent actions of miR-106b in CLL |
| Q38090433 | Context-specific regulation of cancer epigenomes by histone and transcription factor methylation |
| Q24301269 | Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-Cell lymphomas |
| Q38259629 | Critical Role of c-Myc in Acute Myeloid Leukemia Involving Direct Regulation of miR-26a and Histone Methyltransferase EZH2. |
| Q35478969 | Decreased microRNA-214 levels in breast cancer cells coincides with increased cell proliferation, invasion and accumulation of the Polycomb Ezh2 methyltransferase |
| Q43183323 | Deregulation of H3K27 methylation in cancer |
| Q38818485 | Dietary phytochemicals as epigenetic modifiers in cancer: Promise and challenges |
| Q51711294 | Differential expression of enhancer of zeste homolog 2 (EZH2) protein in small cell and aggressive B-cell non-Hodgkin lymphomas and differential regulation of EZH2 expression by p-ERK1/2 and MYC in aggressive B-cell lymphomas. |
| Q33586491 | Disruption of the MYC-miRNA-EZH2 loop to suppress aggressive B-cell lymphoma survival and clonogenicity |
| Q28084911 | Diverse involvement of EZH2 in cancer epigenetics |
| Q33813030 | Down-regulation of miR-101 in endothelial cells promotes blood vessel formation through reduced repression of EZH2 |
| Q36088836 | Downregulation of Plasma MiR-142-3p and MiR-26a-5p in Patients With Colorectal Carcinoma |
| Q38761793 | EBV-negative aggressive NK-cell leukemia/lymphoma: a clinical and pathological study from a single institution |
| Q21091136 | ETS transcription factors control transcription of EZH2 and epigenetic silencing of the tumor suppressor gene Nkx3.1 in prostate cancer |
| Q36365753 | EZH2 Mediates epigenetic silencing of neuroblastoma suppressor genes CASZ1, CLU, RUNX3, and NGFR |
| Q54392744 | EZH2 Y641 mutations in follicular lymphoma. |
| Q28082054 | EZH2 in Bladder Cancer, a Promising Therapeutic Target |
| Q90380014 | EZH2 is upregulated in the proliferation centers of CLL/SLL lymph nodes |
| Q92881078 | EZH2 upregulates the PI3K/AKT pathway through IGF1R and MYC in clinically aggressive chronic lymphocytic leukaemia |
| Q34803805 | EZH2-dependent suppression of a cellular senescence phenotype in melanoma cells by inhibition of p21/CDKN1A expression |
| Q53003254 | EZH2: a potential new target in T-cell lymphoma? |
| Q34561758 | Enhancer of Zeste homolog 2 (EZH2) is overexpressed in recurrent nasopharyngeal carcinoma and is regulated by miR-26a, miR-101, and miR-98. |
| Q34257246 | Enhancer of zeste homolog 2 epigenetically silences multiple tumor suppressor microRNAs to promote liver cancer metastasis. |
| Q38101901 | Epigenetic dysregulation in hepatocellular carcinoma: focus on polycomb group proteins |
| Q37822735 | Epigenetic factors in cancer development: polycomb group proteins |
| Q37823067 | Epigenetic mechanisms in inflammation |
| Q38895512 | Epigenetic mechanisms of cell adhesion-mediated drug resistance in multiple myeloma. |
| Q36956957 | Epigenetic silencing of miR-26A1 in chronic lymphocytic leukemia and mantle cell lymphoma: Impact on EZH2 expression |
| Q51770872 | Epigenetics and MicroRNAs in Cancer. |
| Q37249131 | Epigenetics and ncRNAs in brain function and disease: mechanisms and prospects for therapy. |
| Q53078040 | Expression, regulation and roles of miR-26a and MEG3 in tongue squamous cell carcinoma. |
| Q34419383 | FAS-antisense 1 lncRNA and production of soluble versus membrane Fas in B-cell lymphoma. |
| Q39509421 | FOXP3 and FOXP3-regulated microRNAs suppress SATB1 in breast cancer cells. |
| Q37993339 | Feedback networks between microRNAs and epigenetic modifications in urological tumors. |
| Q34372544 | Forced expression of miR-143 represses ERK5/c-Myc and p68/p72 signaling in concert with miR-145 in gut tumors of Apc(Min) mice |
| Q37835825 | Gene silencing by the Polycomb group proteins and associations with cancer |
| Q47134267 | Gene-body hypermethylation controlled cryptic promoter and miR26A1-dependent EZH2 regulation of TET1 gene activity in chronic lymphocytic leukemia |
| Q87955785 | Genetic and epigenetic influences on the loss of tolerance in autoimmunity |
| Q38509706 | Genetic mutations in epigenetic modifiers as therapeutic targets in acute myeloid leukemia |
| Q26859071 | HIV-associated neuropathogenesis: a systems biology perspective for modeling and therapy |
| Q41740532 | Host miR-26a suppresses replication of porcine reproductive and respiratory syndrome virus by upregulating type I interferons |
| Q28292904 | Human embryonic stem cells and metastatic colorectal cancer cells shared the common endogenous human microRNA-26b |
| Q37371336 | IL-6 upregulation contributes to the reduction of miR-26a expression in hepatocellular carcinoma cells |
| Q33739866 | Identification of miR-26 as a key mediator of estrogen stimulated cell proliferation by targeting CHD1, GREB1 and KPNA2. |
| Q36140942 | Immunohistochemical and genomic profiles of diffuse large B-cell lymphomas: implications for targeted EZH2 inhibitor therapy? |
| Q33633473 | Inactivation of Ezh2 Upregulates Gfi1 and Drives Aggressive Myc-Driven Group 3 Medulloblastoma |
| Q48031592 | Induction of alpha-methylacyl-CoA racemase by miR-138 via up-regulation of β-catenin in prostate cancer cells. |
| Q35141444 | Inhibition of miR-193a expression by Max and RXRα activates K-Ras and PLAU to mediate distinct aspects of cellular transformation |
| Q36790044 | Integrative Analysis Reveals the Transcriptional Collaboration between EZH2 and E2F1 in the Regulation of Cancer-Related Gene Expression |
| Q35042522 | Interferon-γ production by neutrophils during bacterial pneumonia in mice |
| Q39098623 | Interplay between the miRNome and the epigenetic machinery: Implications in health and disease. |
| Q41233785 | Long Non-coding RNA HOTAIR Expression in Diffuse Large B-Cell Lymphoma: In Relation to Polycomb Repressive Complex Pathway Proteins and H3K27 Trimethylation |
| Q34027680 | Lysine-specific demethylase 2B (KDM2B)-let-7-enhancer of zester homolog 2 (EZH2) pathway regulates cell cycle progression and senescence in primary cells. |
| Q41286875 | MUC1-C activates EZH2 expression and function in human cancer cells. |
| Q42731671 | MYC and Prostate Cancer |
| Q26825457 | MYC and the art of microRNA maintenance |
| Q29619979 | MYC on the path to cancer |
| Q34314932 | MYC through miR-17-92 suppresses specific target genes to maintain survival, autonomous proliferation, and a neoplastic state |
| Q26783555 | MYC, Metabolism, and Cancer |
| Q45742884 | MYCN contributes to the malignant characteristics of erythroleukemia through EZH2-mediated epigenetic repression of p21. |
| Q39769505 | MYCN/c-MYC-induced microRNAs repress coding gene networks associated with poor outcome in MYCN/c-MYC-activated tumors. |
| Q89967082 | Manipulating microRNAs for the Treatment of Malignant Pleural Mesothelioma: Past, Present and Future |
| Q36873265 | Mechanisms of epigenetic deregulation in lymphoid neoplasms |
| Q38750019 | MiR-26a and miR-138 block the G1/S transition by targeting the cell cycle regulating network in prostate cancer cells. |
| Q36080088 | MiR-26a enhances autophagy to protect against ethanol-induced acute liver injury. |
| Q47762719 | MiR-26a functions as a tumor suppressor in ambient particulate matter-bound metal-triggered lung cancer cell metastasis by targeting LIN28B-IL6-STAT3 axis |
| Q39178996 | MiR-449c targets c-Myc and inhibits NSCLC cell progression |
| Q58753107 | MiRNA Dysregulation in Childhood Hematological Cancer |
| Q41997354 | MiRNAs in Astrocyte-Derived Exosomes as Possible Mediators of Neuronal Plasticity |
| Q42752709 | MicroRNA Role in Thyroid Cancer Development |
| Q33947119 | MicroRNA miR-124 controls the choice between neuronal and astrocyte differentiation by fine-tuning Ezh2 expression |
| Q35553338 | MicroRNA profiles of t(14;18)-negative follicular lymphoma support a late germinal center B-cell phenotype |
| Q37208449 | MicroRNA profiling and head and neck cancer |
| Q34793627 | MicroRNA regulation of IFN-beta protein expression: rapid and sensitive modulation of the innate immune response |
| Q39703169 | MicroRNA-101 negatively regulates Ezh2 and its expression is modulated by androgen receptor and HIF-1alpha/HIF-1beta |
| Q24633326 | MicroRNA-182-5p targets a network of genes involved in DNA repair |
| Q28280193 | MicroRNA-26a is strongly downregulated in melanoma and induces cell death through repression of silencer of death domains (SODD) |
| Q37689727 | MicroRNA-26a negatively regulates toll-like receptor 3 expression of rat macrophages and ameliorates pristane induced arthritis in rats. |
| Q35273569 | MicroRNA-26a promotes anoikis in human hepatocellular carcinoma cells by targeting alpha5 integrin |
| Q39123359 | MicroRNA-26a promotes tumor growth and angiogenesis in glioma by directly targeting prohibitin |
| Q46255425 | MicroRNA-26a suppresses tumor growth and metastasis of human hepatocellular carcinoma by targeting interleukin-6-Stat3 pathway |
| Q40647567 | MicroRNA-26a-mediated regulation of interleukin-2 expression in transformed avian lymphocyte lines. |
| Q24601263 | MicroRNA-26a/b and their host genes cooperate to inhibit the G1/S transition by activating the pRb protein |
| Q37495218 | MicroRNA-based screens for synthetic lethal interactions with c-Myc |
| Q27013740 | MicroRNA-regulated pathways in hematological malignancies: how to avoid cells playing out of tune |
| Q36602853 | MicroRNAs and Glucocorticoid-Induced Apoptosis in Lymphoid Malignancies |
| Q37852129 | MicroRNAs and epigenetics |
| Q57471217 | MicroRNAs in Autoimmunity and Hematological Malignancies |
| Q34325959 | MicroRNAs in human cancer |
| Q38215733 | MicroRNAs in human lung cancer. |
| Q64234430 | Micromanaging aerobic respiration and glycolysis in cancer cells |
| Q38166839 | Modulation of epigenetic regulators and cell fate decisions by miRNAs |
| Q37970680 | Molecular profiling of aggressive lymphomas |
| Q39004252 | Multifaceted role of the polycomb-group gene EZH2 in hematological malignancies |
| Q35640345 | Myc enforces overexpression of EZH2 in early prostatic neoplasia via transcriptional and post-transcriptional mechanisms |
| Q40871821 | Myc regulates the transcription of the PRC2 gene to control the expression of developmental genes in embryonic stem cells |
| Q39565441 | Myc-mediated repression of microRNA-34a promotes high-grade transformation of B-cell lymphoma by dysregulation of FoxP1 |
| Q37614231 | NPM-ALK up-regulates iNOS expression through a STAT3/microRNA-26a-dependent mechanism. |
| Q49358167 | Nicotine associated breast cancer in smokers is mediated through high level of EZH2 expression which can be reversed by methyltransferase inhibitor DZNepA. |
| Q38045799 | Non-coding RNAs and EZH2 interactions in cancer: long and short tales from the transcriptome. |
| Q37591537 | Non-coding RNAs as direct and indirect modulators of epigenetic regulation |
| Q38166375 | Noncoding RNAs in Acute Myeloid Leukemia: From Key Regulators to Clinical Players |
| Q35251736 | Omega-3 Polyunsaturated Fatty Acids Upregulate 15-PGDH Expression in Cholangiocarcinoma Cells by Inhibiting miR-26a/b Expression |
| Q34890457 | Overexpression of Enhancer of zeste homolog 2 with trimethylation of lysine 27 on histone H3 in adult T-cell leukemia/lymphoma as a target for epigenetic therapy |
| Q34000446 | Overexpression of MYC and EZH2 cooperates to epigenetically silence MST1 expression |
| Q28484272 | PRC2/EED-EZH2 complex is up-regulated in breast cancer lymph node metastasis compared to primary tumor and correlates with tumor proliferation in situ |
| Q64087879 | Pathogenesis and biomarkers of natural killer T cell lymphoma (NKTL) |
| Q28295895 | Pathologically decreased miR-26a antagonizes apoptosis and facilitates carcinogenesis by targeting MTDH and EZH2 in breast cancer |
| Q51747268 | Pleiotropic antitumor effects of the pan-HDAC inhibitor ITF2357 against c-Myc-overexpressing human B-cell non-Hodgkin lymphomas. |
| Q26801380 | Polycomb Group (PcG) Proteins and Human Cancers: Multifaceted Functions and Therapeutic Implications |
| Q57810481 | Polycomb complexes in normal and malignant hematopoiesis |
| Q35103527 | Polycomb genes, miRNA, and their deregulation in B-cell malignancies |
| Q37629613 | Polycomb group protein gene silencing, non-coding RNA, stem cells, and cancer |
| Q38125132 | Polycomb group proteins and MYC: the cancer connection. |
| Q34134903 | Polycomb group proteins: multi-faceted regulators of somatic stem cells and cancer |
| Q38349096 | Polycomb protein EZH2 regulates E2F1-dependent apoptosis through epigenetically modulating Bim expression |
| Q33951701 | Polycomb repressor complex 2 regulates HOXA9 and HOXA10, activating ID2 in NK/T-cell lines |
| Q49885201 | Potential Epigenetic Regulation in the Germinal Center Reaction of Lymphoid Tissues in HIV/SIV Infection |
| Q46078221 | Primary biliary cholangitis: a comprehensive overview |
| Q37417968 | Primate-specific miR-515 family members inhibit key genes in human trophoblast differentiation and are upregulated in preeclampsia |
| Q35871679 | RETRACTED: A TARBP2 mutation in human cancer impairs microRNA processing and DICER1 function |
| Q34043370 | Regulation and Role of EZH2 in Cancer |
| Q37545071 | Regulation and role of post-translational modifications of enhancer of zeste homologue 2 in cancer development |
| Q51733364 | Regulation of Cellular Senescence by Polycomb Chromatin Modifiers through Distinct DNA Damage- and Histone Methylation-Dependent Pathways. |
| Q37418150 | Regulation of microRNAs by epigenetics and their interplay involved in cancer |
| Q92382800 | Research progress on the interactions between long non-coding RNAs and microRNAs in human cancer |
| Q34825705 | Retracted: miR-26a and its Target CKS2 Modulate Cell Growth and Tumorigenesis of Papillary Thyroid Carcinoma |
| Q38812898 | Reversing epigenetic mechanisms of drug resistance in solid tumors using targeted microRNA delivery |
| Q42923456 | Role of microRNAs and microRNA machinery in the pathogenesis of diffuse large B-cell lymphoma |
| Q37810078 | Role of microRNAs in hematological malignancies |
| Q90073171 | Serine Biosynthesis Pathway Supports MYC-miR-494-EZH2 Feed-Forward Circuit Necessary to Maintain Metabolic and Epigenetic Reprogramming of Burkitt Lymphoma Cells |
| Q38728098 | Sialyltransferase ST3GAL6 mediates the effect of microRNA-26a on cell growth, migration, and invasion in hepatocellular carcinoma through the protein kinase B/mammalian target of rapamycin pathway |
| Q98386355 | Small RNA profiles of HTLV-1 asymptomatic carriers with monoclonal and polyclonal rearrangement of the T-cell antigen receptor γ-chain using massively parallel sequencing: A pilot study |
| Q38997197 | Stem Cell-Derived Exosomes, Autophagy, Extracellular Matrix Turnover, and miRNAs in Cardiac Regeneration during Stem Cell Therapy |
| Q38913027 | Strong expression of EZH2 and accumulation of trimethylated H3K27 in diffuse large B-cell lymphoma independent of cell of origin and EZH2 codon 641 mutation |
| Q42289696 | Sustained expression of miR-26a promotes chromosomal instability and tumorigenesis through regulation of CHFR. |
| Q21267232 | Systematic analysis of off-target effects in an RNAi screen reveals microRNAs affecting sensitivity to TRAIL-induced apoptosis |
| Q33629724 | TIMELESS contributes to the progression of breast cancer through activation of MYC. |
| Q40014635 | Targeting Enhancer of Zeste Homolog 2 as a promising strategy for cancer treatment |
| Q38853857 | Targeting Intrinsic and Extrinsic Vulnerabilities for the Treatment of Multiple Myeloma |
| Q90292108 | Tat expression led to increased histone 3 tri-methylation at lysine 27 and contributed to HIV latency in astrocytes through regulation of MeCP2 and Ezh2 expression |
| Q46013515 | Thalidomide exerts distinct molecular antileukemic effects and combined thalidomide/fludarabine therapy is clinically effective in high-risk chronic lymphocytic leukemia. |
| Q24657924 | The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo |
| Q37518164 | The different epidemiologic subtypes of Burkitt lymphoma share a homogenous micro RNA profile distinct from diffuse large B-cell lymphoma |
| Q26822987 | The effects of microRNA on the absorption, distribution, metabolism and excretion of drugs |
| Q37797944 | The guardians of the genome (p53, TA-p73, and TA-p63) are regulators of tumor suppressor miRNAs network |
| Q42063012 | The microRNA-26a target E2F7 sustains cell proliferation and inhibits monocytic differentiation of acute myeloid leukemia cells. |
| Q28271675 | The microRNAs within the DLK1-DIO3 genomic region: involvement in disease pathogenesis |
| Q34039262 | The polycomb protein Ezh2 impacts on induced pluripotent stem cell generation |
| Q28255886 | The role of EZH2 in tumour progression |
| Q38208520 | The role of epigenetics in the biology of multiple myeloma. |
| Q38796729 | The role of microRNA-26a in human cancer progression and clinical application |
| Q38650146 | The role of microRNAs in different types of thyroid carcinoma: a comprehensive analysis to find new miRNA supplementary therapies |
| Q37601781 | The role of microRNAs in endometriosis and associated reproductive conditions |
| Q41017260 | The role of the polycomb repressive complex pathway in T and NK cell lymphoma: biological and prognostic implications. |
| Q38210729 | The role of vitamins and minerals in modulating the expression of microRNA. |
| Q42333838 | The tumor microenvironment disarms CD8+ T lymphocyte function via a miR-26a-EZH2 axis |
| Q34181700 | Trastuzumab produces therapeutic actions by upregulating miR-26a and miR-30b in breast cancer cells |
| Q34590225 | Tumor suppression by miR-26 overrides potential oncogenic activity in intestinal tumorigenesis |
| Q34121755 | Tumor-suppressive microRNA-22 inhibits the transcription of E-box-containing c-Myc target genes by silencing c-Myc binding protein |
| Q38074267 | Uncovering the DNA methylome in chronic lymphocytic leukemia |
| Q28259732 | c-MYC Generates Repair Errors via Increased Transcription of Alternative-NHEJ Factors, LIG3 and PARP1, in Tyrosine Kinase-Activated Leukemias |
| Q85198781 | c-Myc-mediated epigenetic silencing of MicroRNA-101 contributes to dysregulation of multiple pathways in hepatocellular carcinoma |
| Q34509582 | c-Rel regulates Ezh2 expression in activated lymphocytes and malignant lymphoid cells |
| Q37443693 | hsa-miR-376c-3p Regulates Gastric Tumor Growth Both In Vitro and In Vivo |
| Q47134084 | let-7b and let-7c microRNAs promote histone H2B ubiquitylation and inhibit cell migration by targeting multiple components of the H2B deubiquitylation machinery |
| Q53618163 | miR expression in MYC-negative DLBCL/BL with partial trisomy 11 is similar to classical Burkitt lymphoma and different from diffuse large B-cell lymphoma. |
| Q24604354 | miR-101 is down-regulated in glioblastoma resulting in EZH2-induced proliferation, migration, and angiogenesis |
| Q37813189 | miR-20a and miR-290, multi-faceted players with a role in tumourigenesis and senescence |
| Q36917611 | miR-26a enhances miRNA biogenesis by targeting Lin28B and Zcchc11 to suppress tumor growth and metastasis. |
| Q92761624 | miR-26a promotes hepatocellular carcinoma invasion and metastasis by inhibiting PTEN and inhibits cell growth by repressing EZH2 |
| Q38826529 | miR-342-3p regulates MYC transcriptional activity via direct repression of E2F1 in human lung cancer. |
| Q42182365 | miR26a modulates Th17/T reg balance in the EAE model of multiple sclerosis by targeting IL6. |
| Q34286618 | miRNAs and cancer: an epigenetics view |
| Q24628889 | miRNAs in human cancer |
| Q55054170 | microRNA-26a induces a mitochondrial apoptosis mediated by p53 through targeting to inhibit Mcl1 in human hepatocellular carcinoma. |
| Q35753974 | microRNA-425-5p is upregulated in human gastric cancer and contributes to invasion and metastasis in vitro and in vivo |